CRNA Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy; and Solid Biosciences Inc. to evaluate circVec and POLARIS-101 technology for genetic heart diseases. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.…
Industry Peers
BiotechnologyKey Statistics
About Circio Holding (OSL: CRNA)
›
Circio Holding (OSL: CRNA) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 9.330 NOK on 19 November 2026, up 910.8% over 52 weeks. Its 52-week range is 0.9100 NOK to 15.70 NOK: the price is 40.6% below the high and 925.3% above the low.
Its market capitalisation is 2.71B NOK.
Circio Holding reports return on equity of 367.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 539.01M NOK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 14 April 2027.